Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Retains Simvastatin Share As New Entrants Struggle To Meet Demand

Executive Summary

Generic companies may find it difficult to assess how much supply to produce when a large product loses 180-day exclusivity, comments by Teva Pharmaceuticals USA CEO William Marth suggest
Advertisement

Related Content

Generic Drug Service, Not Pricing, Is Key Performance Factor – Lehman’s Silver
Generic Drug Service, Not Pricing, Is Key Performance Factor – Lehman’s Silver
Financial Analysts Roundtable Part II: Changes On Capitol Hill, FDA’s Risk Threshold And The Future Of The Cholesterol Market
Generic Launches Are Capturing More Share More Quickly, Teva Says
Generic Launches Are Capturing More Share More Quickly, Teva Says
Advertisement
UsernamePublicRestriction

Register

PS048087

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel